Givaudan SA CEO Giles Andrier told investors that potential tariffs levied by the Trump Administration should not impact sales of its finished products to customers, as “we actually make in the US all of the things that we sell in the US.”
Givaudan Unfazed By Potential Tariffs On Finished Goods: US-Sold Products Also Made in US – CEO
Givaudan CEO Giles Andrier told analysts during the Swiss firm’s 2024 sales presentation that strong sales in Q4 were not impacted by a pre-buying of products and ingredients late in the year, as experienced by other companies, in anticipation of potential new tariffs imposed by the Trump administration.

More from Policy & Regulation
Single-use packaging producers subject to California’s SB 54 recycling law, which implements a statewide EPR plan, should continue to prepare for its implementation, even as they enter a ‘prolonged period of uncertainty,’ says consultant Michael Washburn.
Data from the US Food and Drug Administration indicated that two hair dye ingredients are formulated in eye makeup and dermal application products, prompting a Cosmetic Ingredient Review panel to conclude one dye is unsafe for such uses and discouraging those uses in the other dye.
Preliminary registration data released by FDA offers a first glimpse of the Modernization of Cosmetics Regulation Act’s impact on information the agency has at hand.
Counterfeit beauty products cost the US industry an estimated $3bn in 2023, says a trade expert during the Personal Care Products Council’s Beauty Collective Summit.
More from HBW Insight
Vitawell seeking to empower consumers left confused by the vast array of dietary supplements available to them in the UK.
Tariffs on imports from China and look at eliminating self-affirmed GRAS pathway introduced under Trump while DoJ Consumer Protection Branch also continues supplement sector priorities enduring across administrations.
Round up of the latest appointments: PAGB names vice presidents; Activ'Inside gets first US head; EMA elects management board chair.